innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer
The tissue factor-directed antibody-drug conjugate tisotumab vedotin lengthened survival compared with chemotherapy in cervical cancer that had progressed after first-line treatment, at the cost of eye and nerve side effects.
Overview
Phase 3 trial of 502 patients with recurrent or metastatic cervical cancer after one or two prior systemic regimens randomised to tisotumab vedotin or investigator's choice chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed).
Median overall survival was 11.5 versus 9.5 months (hazard ratio 0.70), progression-free survival 4.2 versus 2.9 months and objective response 17.8 versus 5.2 percent; ocular events, peripheral neuropathy and bleeding were the characteristic toxicities.
- Median overall survival 11.5 vs 9.5 months; hazard ratio 0.70.
- Objective response 17.8 percent vs 5.2 percent.
Tisotumab vedotin is the standard second-line treatment for recurrent cervical cancer after chemo-immunotherapy, with a mandatory eye-care protocol.
- Modest absolute gains.
- Conjunctivitis and keratitis require prophylactic eye drops and regular examinations.
Similar pages
not linked directly; found by shared links- PersonIgnace Vergote
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tisotumab vedotin.
- Key paperGOG 240: bevacizumab added to chemotherapy for advanced cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperKEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- TargetTissue factor
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tisotumab vedotin.
- Key paperEMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With
Shares Tisotumab vedotin, Recurrent or metastatic cervical cancer.
- PersonBradley J. Monk
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tisotumab vedotin.